Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes

[1]  R. Stone,et al.  Autoimmunity and Inflammation in Myelodysplastic Syndromes , 2016, Acta Haematologica.

[2]  J. Čermák,et al.  Protein Carbonylation in Patients with Myelodysplastic Syndromes , 2015 .

[3]  F. Sotgia,et al.  Metastasis and Oxidative Stress: Are Antioxidants a Metabolic Driver of Progression? , 2015, Cell metabolism.

[4]  A. Gonçalves,et al.  Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study , 2015, Free radical research.

[5]  A. Thiel,et al.  IL‐17‐producing CD4+ T cells contribute to the loss of B‐cell tolerance in experimental autoimmune myasthenia gravis , 2015, European journal of immunology.

[6]  R. M. de Freitas,et al.  HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study , 2015, BMJ Open.

[7]  David W. Johnson,et al.  Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study , 2015, BMJ Open.

[8]  Sheng Wei,et al.  The inflammatory microenvironment in MDS , 2015, Cellular and Molecular Life Sciences.

[9]  M. Atalay,et al.  Validation of protein carbonyl measurement: A multi-centre study , 2014, Redox biology.

[10]  A. Verma,et al.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. , 2014, Blood.

[11]  P. Fenaux,et al.  Myelodysplastic syndromes , 2014, The Lancet.

[12]  Bing Li,et al.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. , 2014, Leukemia research.

[13]  S. Reddy,et al.  Reactive oxygen species in inflammation and tissue injury. , 2014, Antioxidants & redox signaling.

[14]  J. Čermák,et al.  Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload , 2014, Oxidative medicine and cellular longevity.

[15]  C. Fletcher,et al.  Diagnostic histopathology of tumors , 2013 .

[16]  K. Pimková,et al.  The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function , 2013, TheScientificWorldJournal.

[17]  J. Čermák,et al.  Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome , 2013, Journal of Hematology & Oncology.

[18]  M. Brown,et al.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer , 2013, Journal of Hematology & Oncology.

[19]  Sun-Yuan Kung,et al.  Fast subcellular localization by cascaded fusion of signal-based and homology-based methods , 2011, Proteome Science.

[20]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[21]  J. Čermák,et al.  Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia , 2011, Proteome Science.

[22]  K. Saigo,et al.  Oxidative Stress Levels in Myelodysplastic Syndrome Patients: Their Relationship to Serum Ferritin and Haemoglobin Values , 2011, The Journal of international medical research.

[23]  F. Regnier,et al.  Differential carbonylation of proteins as a function of in vivo oxidative stress. , 2011, Journal of proteome research.

[24]  M. Cazzola,et al.  Ring sideroblasts and sideroblastic anemias , 2011, Haematologica.

[25]  C. Hershko.  Pathogenesis and management of iron toxicity in thalassemia , 2010, Annals of the New York Academy of Sciences.

[26]  N. Gattermann,et al.  Iron overload in MDS—pathophysiology, diagnosis, and complications , 2010, Annals of Hematology.

[27]  D. Butterfield,et al.  Protein carbonylation. , 2010, Antioxidants & redox signaling.

[28]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[29]  G. Mufti,et al.  IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome , 2009, British journal of haematology.

[30]  R. Ahmad,et al.  Oxidative stress and antioxidant status in patients with chronic myeloid leukemia , 2008, Indian Journal of Clinical Biochemistry.

[31]  E. Fibach,et al.  Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome , 2007, European journal of haematology.

[32]  Y. Rana,et al.  Oxidative stress in red blood cells in haemoglobinuric buffaloes. , 2007 .

[33]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[34]  E. Vichinsky,et al.  Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell disease , 2006, British journal of haematology.

[35]  E. Stadtman,et al.  Chemical Modification of Proteins by Reactive Oxygen Species , 2006 .

[36]  Roberto Colombo,et al.  Protein carbonylation, cellular dysfunction, and disease progression , 2006, Journal of cellular and molecular medicine.

[37]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Bargagli,et al.  Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis , 2005, Proteomics.

[39]  M. Cazzola,et al.  Myelodysplastic syndromes--coping with ineffective hematopoiesis. , 2005, The New England journal of medicine.

[40]  J. KOOPMANSS.,et al.  Acute phase reaction and acute phase proteins , 2005 .

[41]  D. Bowen,et al.  Oxidative Stress and the Myelodysplastic Syndromes , 2003, International journal of hematology.

[42]  W. Dröge.  Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[43]  B. Fanburg,et al.  Reactive oxygen species in cell signaling. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[44]  E. Stadtman,et al.  Protein Oxidation , 2000, Annals of the New York Academy of Sciences.

[45]  M. Cappellini,et al.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? , 2000, The hematology journal : the official journal of the European Haematology Association.

[46]  J. L. Le Gall,et al.  Insulin resistance-associated hepatic iron overload. , 1999, Gastroenterology.

[47]  S. Altamentova,et al.  Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. , 1997, Biochemistry.

[48]  R. Larson,et al.  Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. , 1996, Leukemia.

[49]  R. Lathe.  Phd by thesis , 1988, Nature.

[50]  M. Zurlo,et al.  Insulin dependent diabetes in thalassaemia. , 1988, Archives of disease in childhood.